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A B S T R A C T
Purpose
Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell
lung cancer (NSCLC), regardless of brainmetastases status andwith or without prior therapywith an
inhibitor of the ALK protein. Data are presented from a phase II trial (ASCEND-2) in which ceritinib
efficacy and safety were evaluated in patients who had ALK-rearranged NSCLC previously treated
with at least one platinum-based chemotherapy and who had experienced progression during
crizotinib treatment as their last prior therapy.
Patients and Methods
Patients with advanced ALK-rearranged NSCLC, including those with asymptomatic or neurologi-
cally stable baseline brain metastases, received oral ceritinib 750 mg/d. Whole-body and intracranial
responses were investigator assessed (according to RECIST version 1.1). Patient-reported out-
comes were evaluated with the Lung Cancer Symptom Scale and European Organisation for
Research and Treatment of Cancer surveys (the core-30 and the 13-item lung cancer–specific
quality-of-life questionnaires).
Results
All 140 patients enrolled had received two or more previous treatment regimens, and all patients had
received crizotinib. Themedianduration of exposure and the follow-up timewith ceritinibwere 8.8months
(range, 0.1 to 19.4 months) and 11.3 months (range, 0.1 to 18.9 months), respectively. Investigator-
assessed overall response rate was 38.6% (95% CI, 30.5% to 47.2%). Secondary end points, all in-
vestigator assessed, included disease control rate (77.1%; 95% CI, 69.3% to 83.8%), time to response
(median, 1.8months; range, 1.6 to 5.6months), duration of response (median, 9.7months; 95%CI, 7.1 to
11.1 months), and progression-free survival (median, 5.7 months; 95% CI, 5.4 to 7.6 months). Of 100
patients with baseline brain metastases, 20 had active target lesions at baseline; investigator-assessed
intracranial overall response rate was 45.0% (95% CI, 23.1% to 68.5%). The most common adverse
events (majority, grade 1 or 2) for all treated patientswere nausea (81.4%), diarrhea (80.0%), and vomiting
(62.9%). Patient-reported outcomes showed a trend toward improved symptom burden. The global
quality-of-life score was maintained during treatment.
Conclusion
Consistent with its activity in ASCEND-1, ceritinib treatment provided clinically meaningful and
durable responses with manageable tolerability in chemotherapy- and crizotinib-pretreated patients,
including those with brain metastases.
J Clin Oncol 34:2866-2873. © 2016 by American Society of Clinical Oncology
INTRODUCTION
The discovery of oncogenic-driver alterations and
the subsequent development of targeted thera-
peutics against these mutations have been key
advancements in the treatment of non–small-cell
lung cancer (NSCLC).1 ALK rearrangements, most
commonly EML4-ALK fusion, occur in approxi-
mately 2% to 7% of patients with NSCLC, and
clinical data have demonstrated the success of
therapeutic approaches targeting the ALK protein
2866 © 2016 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 24 • AUGUST 20, 2016
in this patient group.2-5 The first ALK-targeted agent approved in
patients with ALK-rearranged NSCLC was crizotinib, which has
become a standard of care in this group after results from two
phase III trials showed its superiority compared with chemo-
therapy in both the first- and second-line settings.2,5,6 However,
despite these promising results, patients eventually experience
disease progression because of acquired resistance through sec-
ondary ALK mutations (eg, gatekeeper L1196 mutation) and
alternative oncogenic pathways.7-9 The rate of brain metastases
in ALK-positive patients with NSCLC, 30% to 50%,10,11 is poorly
understood12. In chemotherapy-pretreated patients without
baseline brain metastases who receive crizotinib, approximately
20% experience progression in the brain as a new site of disease.12
Strategies to overcome crizotinib-resistant disease, including
highly potent, structurally distinct, second-generation ALK in-
hibitors, are being developed. Among these, ceritinib was granted
accelerated approval by the US Food and Drug Administration in
April 2014 for the treatment of patients with ALK-positive met-
astatic NSCLCwho have experienced progression during treatment
with or who are intolerant to crizotinib.13 Ceritinib has since
been approved by the European Medicines Agency14 and in nu-
merous countries worldwide. Other second-generation agents
include alectinib15,16 and brigatinib (AP26113)17; promising
clinical outcomes have been reported in patients with ALK-
rearranged NSCLC for each agent; importantly, all have shown
evidence of intracranial efficacy.16,18,19
Ceritinib (LDK378, Novartis) is a selective oral inhibitor of
ALK with a 20-fold greater potency than crizotinib in enzymatic
assays. In vivo analyses with a rat model demonstrated penetration
of ceritinib across the blood–brain barrier, with a brain-to-blood
exposure (area under the curve from 0 to infinity) ratio of ap-
proximately 15%.20 Results from the phase I dose-escalation/dose-
expansion ASCEND-1 study demonstrated robust antitumor
efficacy (intracranially and extracranially) in heavily pretreated
patients with ALK-rearranged NSCLC, including both ALK
inhibitor–naı̈ve and ALK inhibitor–pretreated patients.4,13,21
Ceritinib activity was observed in patients with or without
crizotinib resistance mutations.4
The efficacy and safety results for ceritinib 750 mg/d in
a heavily pretreated patient population are reported for 140 pa-
tients with ALK-rearranged NSCLC enrolled in the ASCEND-2
(NCT01685060) phase II study. Patients enrolled had received
two or more prior lines of antineoplastic therapy, including
platinum-based chemotherapy, and all patients had experienced
progression during crizotinib treatment as the last therapy before
starting ceritinib. Ceritinib activity is also reported for patients




Eligible patients had locally advanced/metastatic ALK-rearranged NSCLC
confirmed by US Food and Drug Administration–approved fluorescent in situ
hybridization (FISH) assay at local sites (confirmation by Novartis-designated
central laboratory was required when ALK documentation was unavailable).
Other key inclusion criteria included a WHO performance status (PS) of 2 or
less andmeasurable disease according to RECIST (Response Evaluation Criteria
in Solid Tumors), version 1.1. All patients must have received prior treatment
with at least one platinum-based chemotherapy regimen and crizotinib. Prior
treatment with any ALK inhibitor other than crizotinib was not permitted, and
crizotinib must have been the last systemic antineoplastic therapy prior to
ceritinib initiation. Progression during crizotinib treatment, or within 30 days of
last dose, was required.
Before starting ceritinib, all crizotinib-related toxicities had to have
resolved to Common Terminology Criteria for Adverse Events (CTCAE)
grade 2 or lower. Patients with asymptomatic or neurologically stable brain
metastases (for $ 2 weeks before study entry) were eligible. Prior ra-
diotherapy to the brain must have been completed at least 2 weeks before
ceritinib treatment started. Key exclusion criteria are provided in the
Appendix Methods (online only).
Study Design
Eligible patients in this single-arm, open-label, multicenter, phase II
study received ceritinib 750 mg/d on a continuous dosing schedule.
Treatment continued until radiologically documented disease progression
by investigator (RECIST, version 1.1), unacceptable toxicity, or withdrawal
of consent occurred. Treatment beyond progression was permitted in
patients who were still experiencing clinical benefit. The primary objective
was to demonstrate antitumor activity measured by investigator-assessed
overall response rate (ORR).
Secondary objectives included response-related end points assessed
by investigator and blinded independent review committee (BIRC), overall
survival (OS), safety, and patient-reported outcomes (PROs).
Prior to study initiation, the protocol was reviewed and approved by the
local human investigations committee at each participating site. All patients
provided written informed consent. The study was conducted in accordance
with the ethics of the Declaration of Helsinki and Good Clinical Practice
Guidelines of the International Conference on Harmonization.
Study Assessments
Efficacy analysis. Tumor assessments were performed at baseline
and every 8 weeks (6 1 week) from the start of ceritinib treatment, by using
contrast-enhanced computerized tomography or magnetic resonance
imaging. Scans of the chest, upper abdomen, and brain were performed
in all patients at baseline; brain scans were only performed at sub-
sequent assessments in patients with brain lesions at baseline. A con-
sistent imaging modality was required throughout the study.
Investigator-assessed, whole-body (extra- and intracranial disease
sites) tumor responses were determined per RECIST, version 1.1, for ORR,
disease control rate (DCR), time to response (TTR), duration of re-
sponse (DOR), and progression-free survival (PFS). OS was also cal-
culated. Intracranial responses (overall intracranial response rate [OIRR] and
intracranial disease control rate [IDCR]) were calculated in patients with
baseline brain metastases when a target lesion in the brain was identified.
Selection as a target lesion indicated that the lesion was active (a new or
existing lesion that progressed after local therapy). As a result, patients
with brain metastases previously treated with radiotherapy whose le-
sions had not subsequently progressed were not included in the ana-
lyses. Supporting analyses by BIRC were conducted for whole-body and
intracranial responses.
Safety analysis. Safety was monitored at baseline and at every sub-
sequent visit. Assessments of physical condition, ECG, PS, and laboratory
parameters were performed. All adverse events (AEs) were recorded and
graded according to the CTCAE (version 4.03).
PROs analysis. The European Organisation for Research and Treatment
of Cancer core-30 quality-of-life questionnaire (QLQ-C30, version 3.0)
and complementary 13-item lung cancer–specific questionnaire (QLQ-
LC13, version 1.0), along with the Lung Cancer Symptom Scale (LCSS),
were used to evaluate functioning, symptom impact, and treatment-
related AEs. Details are provided in the Appendix Methods.
www.jco.org © 2016 by American Society of Clinical Oncology 2867
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Statistical Analyses
Data sets. All patients who received at least one dose of ceritinib were
included in the efficacy (full analysis set [FAS]) and safety (safety set)
analyses. Supportive efficacy analyses were performed in the per-protocol
set (PPS), which included patients who had no major protocol deviations
(Appendix Table A1, online only) and who had adequate tumor assess-
ments at baseline and follow-up (. 7 weeks after starting treatment, except
when progressive disease [PD] was observed before 7 weeks, in which case
the patient was always included in the PPS set).
The study objective was met at the time of the primary analysis, which
was based on a data cutoff date of February 26, 2014. This is an updated
analysis of the data that is based on a cutoff date of August 13, 2014.
Efficacy analysis. Per RECIST, version 1.1, confirmation of response
at 4 weeks or more after initial documentation was required for de-
termination of best overall response (BOR). On the basis of an exact
binomial distribution, approximately 137 patients were required to test
a null hypothesis of an ORR# 25% versus a target ORR of$ 38%, with
a one-sided a of .025 and 90% power. On the basis of 137 patients, if 45
or more responses were observed (estimated ORR of $ 32.8%), the
null hypothesis would be rejected. Additional details are available in
Appendix Methods.
PROs analysis. Details are available in Appendix Methods. For each




Across 51 global sites, from December 2012 to September
2013, 140 patients with ALK-rearranged advanced NSCLC were
enrolled. All patients received at least one dose of ceritinib
750 mg/d. The median follow-up time was 11.3 months (range,
0.1 to 18.9 months; Appendix Table A2, online only). Baseline
demographics and disease characteristics are listed in Table 1.
Most patients were white or Asian and had a WHO PS of 1 or
less. At study entry, 100 patients (71.4%) had brain metastases,
72.0% of whom had received prior brain radiation; the median
time from completion of prior radiotherapy to the start of
ceritinib was 6.2 months (range, 0.5 to 54.0 months). Patients
were heavily pretreated; all patients had received two or more
prior lines of therapy including crizotinib; 56.4% had received
three or more prior lines of treatment. Crizotinib was the last
therapy received prior to initiation of ceritinib treatment; all
patients experienced progression on crizotinib.
Efficacy
The investigator-assessed ORR was 38.6% (95% CI, 30.5%
to 47.2%; Table 2). The DCR was 77.1% (95% CI, 69.3% to
83.8%). Among patients with measurable disease at baseline
and at least one postbaseline assessment, tumor burden was
reduced from baseline in 75.2% of patients (Fig 1A). Supportive
analyses were performed with the PPS (n = 128), which ex-
cluded 12 patients (8.6%) who had major protocol deviations
(exclusions listed in Appendix Table A1; efficacy data in Ap-
pendix Tables A3 and A4, online only). Supportive efficacy
analyses were also performed with the FAS by BIRC assessment
(N = 140) and with the PPS by BIRC assessment (n = 102),
which, in addition to the 12 patients who had major protocol
deviations, excluded 26 patients (18.6%) who did not have
baseline target lesions and/or had no valid baseline tumor
assessment (Appendix Table A1). The BOR with the FAS and
the PPS by BIRC assessment was supportive of investigator
assessments (Appendix Table A4).
Responses by investigator assessment were rapid (median
TTR 1.8 months; range, 1.6 to 5.6 months) and durable
(median DOR, 9.7 months; 95% CI, 7.1 to 11.1). The median
investigator-assessed PFS was 5.7 months (95% CI, 5.4 to 7.6).
Table 1. Patient Demographic and Disease Characteristics (by investigator,
unless otherwise specified)
Characteristic
No. (%) of Patients With
ALK-Rearranged NSCLC (N = 140)














Squamous cell carcinoma 3 (2.1)
Mucinous adenocarcinoma 2 (1.4)
Adenosquamous cell carcinoma 1 (0.7)
Bronchioalveolar carcinoma 1 (0.7)
Papillary serous 1 (0.7)
Undifferentiated carcinoma 1 (0.7)
Other 2 (1.4)






No. of target lesions at baseline
1 60 (42.9)
$ 2 80 (57.1)
No. of target lesions at baseline (by BIRC)
0 26 (18.6)
1 37 (26.4)
$ 2 75 (53.6)
Missing baseline 2 (1.4)




. 3 31 (22.1)
Median (range) time since most recent
relapse/progression, months
1.2 (0.2-15.9)
Prior radiotherapy to the brain*
No prior radiotherapy 28 (28.0)
Prior radiotherapy 72 (72.0)
Time elapsed from prior radiotherapy to
the brain to first dose of ceritinib,
months
Median (range) 6.2 (0.5-54.0)
# 3 months prior 21 (29.2)
. 3 months prior 51 (70.8)
Abbreviations: BIRC, blinded independent review committee; ECOG, Eastern
Cooperative Oncology Group; NSCLC, non–small-cell lung cancer.
*In patients with brain metastases at study entry (n = 100).
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The median OS was 14.9 months (95% CI, 13.5 to not
evaluable), and the 12-month OS rate was 63.8% (95% CI,
54.9% to 71.4%). Data from 81 patients (57.9%) were censored
for OS; of these, 72 patients (51.4%) were alive at cutoff.
Efficacy in patients with brain metastases at baseline. A pre-
planned subgroup analysis of whole-body efficacy was conducted
in patients with baseline brain metastases (n = 100). Investigator-
assessed ORR in patients with baseline brain metastases was
33.0% (95% CI, 23.9% to 43.1%), the DCR was 74.0% (95% CI,
64.3% to 82.3%), the median DOR was 9.2 months (95% CI, 5.5 to
11.1 months), and the median PFS was 5.4 months (95% CI, 4.7 to
7.2 months; Table 2). BIRC assessment of efficacy in patients with
baseline brain metastases was supportive of these outcomes
(Appendix Table A4).
Intracranial responses in patients with active brain metastases
at baseline. Intracranial responses were evaluated in 20 patients
with investigator-assessed measurable brain lesions selected as
active target lesions per RECIST, version 1.1, at study entry.
Objective intracranial responses were reported in 45.0% (95% CI,
23.1% to 68.5%; as shown by the brain scans of two patients with
intracranial response; Appendix Fig A1, online only), and an
IDCR of 80.0% (95% CI, 56.3% to 94.3%) was achieved (Table 3).
BIRC analysis of intracranial responses was supportive (Appendix
Table A5, online only).
Treatment Exposure
The median duration of ceritinib exposure for all patients
was 8.8 months (range, 0.1 to 19.4 months); the median relative
dose intensity was 84.9% (range, 37.5% to 100.0%). The
median duration of exposure was 8.6 months (range, 0.1 to
19.4 months) in patients with baseline brain metastases. Dose
interruptions (for at least 1 day of treatment) occurred in
75.7% of patients, of which 85.8% were attributable to AEs. At
least one dose reduction was required in 54.3% of patients, of
which 84.2% were due to AEs. The median time to dose re-
duction was 1.6 months (range, 0.2 to 13.5 months), and
reductions occurred throughout the dosing period.
Safety
Table 4 summarizes AEs reported by 20% or more of pa-
tients and grade 3 to 4 AEs reported by 2% or more of patients.
All patients experienced at least one AE, suspected to be drug
related in 96.4% of patients. AEs that resulted in treatment
discontinuation were reported in 7.9%, but no single AE pre-
dominated. Common GI AEs (eg, nausea, diarrhea, and vom-
iting) were most prevalent; greater than 75% of patients
experienced drug-related nausea or diarrhea. Most drug-related
nausea, diarrhea, and vomiting were grade 1 or 2 and were
reported at grade 3 or 4 in 5.7%, 6.4%, and 4.3% of patients,
respectively. Only 2.1% discontinued ceritinib treatment be-
cause of nausea, diarrhea, and vomiting.
Overall, grade 3 to 4 AEs were reported in 71.4% of patients;
45.7% experienced grade 3 to 4 AEs suspected to be drug related.
The most common drug-related grade 3 to 4 AEs were elevated
ALT and g-glutamyltransferase, which occurred in 15.7% and
9.3%, respectively. Serious AEs (SAEs) were reported in 40.7% of
patients; 17.1% experienced SAEs suspected to be drug related.
Pneumonitis and QTc prolongation (suspected to be drug related)
occurred at any grade in 1.4% and 7.9% of patients, respectively;
grade 4 pneumonitis and grade 3 QTc prolongation each oc-
curred in one patient (0.7%). Other important known adverse
drug reactions of ceritinib include hyperglycemia and brady-
cardia; no drug-related grade 3 or 4 occurrences were reported for
either AE.
PROs
Compliance was high; greater than 90% of patients com-
pleted the QLQ-C30, QLQ-LC13, and LCSS questionnaires
through cycle 13 of the study. Patients reported no worsening in
cancer symptoms during treatment and trended toward im-
provement in lung-related symptoms (ie, cough, pain, and
dyspnea) from baseline by LCSS; the mean change from baseline
of symptom burden score ranged from 21.4 to 26.2 (Fig 2A).
Results from the QLQ-LC13 were consistent with these data.
The QLQ-C30 symptom score indicated that patients re-
ported worse GI-related symptoms (from baseline) throughout
treatment; mean changes from baseline ranged from 23.6 to
+31.8 (Fig 2B). Diarrhea remained consistently worse from
baseline throughout treatment (mean change from baseline
QLQ-C30 symptom score, +24.5 to +31.8). Although nausea
and vomiting were also consistently worse than baseline, an
improvement in these symptoms was observed from early to
late treatment cycles. Overall, health-related quality of life
(QOL) was generally maintained during treatment, and no
substantial change from baseline was observed in the QLQ-C30
global QOL (mean change from baseline, 21.5 to +4.6) or
function scale score (Fig 2C).








Study Entry (n = 100)
No. (%) of patients by
best overall response
CR 4 (2.9) 4 (3.1) 0
PR 50 (35.7) 50 (39.1) 33 (33.0)
SD 54 (38.6) 53 (41.4) 41 (41.0)
PD 19 (13.6) 17 (13.3) 16 (16.0)
UNK 13 (9.3) 4 (3.1) 10 (10.0)
ORR
No. (%) of patients 54 (38.6) 54 (42.2) 33 (33.0)
95% CI 30.5 to 47.2 33.5 to 51.2 23.9 to 43.1
DCR
No. (%) of patients 108 (77.1) 107 (83.6) 74 (74.0)
95% CI 69.3 to 83.8 76.0 to 89.5 64.3 to 82.3
DOR, months
Median 9.7 — 9.2
95% CI 7.1 to 11.1 5.5 to 11.1
PFS, months
Median 5.7 — 5.4
95% CI 5.4 to 7.6 4.7 to 7.2
Abbreviations: CR, complete response; DCR, disease control rate (CR + PR +
SD); DOR, duration of response; FAS, full analysis set; ORR, overall response
rate (CR + PR); PD, progressive disease; PFS, progression-free survival; PPS,
per-protocol set; PR, partial response; SD, stable disease; UNK, unknown.
www.jco.org © 2016 by American Society of Clinical Oncology 2869
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DISCUSSION
Ceritinib resulted in significant and durable clinical activity in
patients with ALK-rearranged NSCLC who had experienced treat-
ment failure with multiple prior antineoplastic treatment regimens,
including crizotinib.2 Whole-body and intracranial responses were
reported in those patients with brain metastases at study entry, in-
cluding patients with target lesions in the brain. The incidence and
type of AEs were consistent with those reported for the ASCEND-1
study, and no new or unexpected SAEs were reported.4,21 GI AEs
were the most prevalent; however, most were grade 1 or 2 and were
manageable with dose interruption/reduction. In addition, PROs
suggested an improvement in lung symptoms, and the global QOL
score was maintained throughout therapy.
The results reported in this study support those reported
for the group of 163 patients previously treated with crizotinib
in ASCEND-1.21 The investigator-assessed DCR was consistent



































































Investigator review (N = 140)
Median progression-free
survival (95% CI)
5.7 (5.4 to 7.6)
7.2 (5.4 to 9.0)BIRC (N = 140)
140 113 88 63 52 43 25 11 7 1 0Investigator review































response (95% CI) 
9.7 (7.1 to 11.1) Investigator review (n = 54)





Investigator review 54 53 43 33 26 14 1 056
BIRC 50 49 36 27 24 13 0038
Fig 1. (A) Waterfall plot of best percentage
change from baseline by investigator review
(n = 125 with measurable disease at baseline
and at least one postbaseline assessment
without unknown response for target lesion or
overall response [includes 114 patients with
best percentage change from baseline data
available, . 0%, , 0%, or 0%, shown in the
figure and 11 patients, not shown, with
a percentage change in the target lesion
available but contradicted by overall lesion
response, progressive disease]). (B) Duration
of response in all patients with ALK-rear-
ranged non–small-cell lung cancer (NSCLC)
who responded to ceritinib treatment (n = 54
by investigator; n = 50 by blinded independent
review committee [BIRC]). (C) Progression-
free survival in all patients with ALK-rear-
ranged NSCLC (N = 140).
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between the two studies (ASCEND-2: 77.1% [95% CI, 69.3% to
83.8%]; ASCEND-1: 74.2% [95% CI, 66.8% to 80.8%]).23 The
ORR in ASCEND-2 (38.6%; 95% CI, 30.5% to 47.2%) was lower
than that reported in ASCEND-1 (56.4%; 95% CI, 48.5% to
64.2%), and both were investigator assessed.24 However, both the
median DOR in patients who achieved a response and the median
PFS in all patients in ASCEND-2 (DOR, 9.7 months [95% CI, 7.1
to 11.1 months]; PFS, 5.7 months [95% CI, 5.4 to 7.6 months])
were similar to those reported for ASCEND-1 (DOR, 8.3 months
[95% CI, 6.8 to 9.7 months]; PFS 6.9 months [95% CI, 5.6 to
8.7 months])24; each was investigator assessed in both studies, and
CIs overlapped.
Results reported for ASCEND-2 and ASCEND-1 were gen-
erally consistent; however, several differences between the studies
exist that do not facilitate their direct comparison. The proportion
of patients evaluated with a single-target lesion at baseline was
42.9% in ASCEND-2 compared with 24.8% in ASCEND-1. Prior
studies suggest that selection of fewer target lesions could result in
a lower response compared with studies that included a higher
number of target lesions,25 as supported by the results reported
here. All patients enrolled on ASCEND-2 had experienced pro-
gression during prior crizotinib treatment. Despite previous
progression during treatment with an ALK inhibitor, the sub-
sequent median investigator-assessed DOR with ceritinib treat-
ment in these patients was 9.7 months.
Ceritinib achieved whole-body and intracranial responses in
patients with baseline brain metastases, a common site of pro-
gression during crizotinib treatment.12 Intracranial activity has
been reported in crizotinib-treated patients; the OIRR in
22 patients with previously untreated measurable lesions in
the brain was 18%, far lower than the systemic ORR of 53%;
both were investigator assessed.12 In contrast, in this study, the
investigator-assessed OIRR after ceritinib treatment in 20
patients with baseline brain metastases was 45.0%, despite
selection of active target lesions, and the IDCR was 80.0%;
however, the two study populations cannot be fairly compared,
because 14 of the 20 patients included in this analysis of in-
tracranial efficacy had previously received local treatment, and
the sample sizes were small, which also precluded investigation
of efficacy as a function of prior radiotherapy. Furthermore,
patients in this study had already experienced progression
during crizotinib treatment, whereas those patients whose
disease responded to crizotinib were ALK inhibitor naı̈ve. These
data, together with emerging evidence for intracranial efficacy
with other second-generation ALK inhibitors,16,18 suggest that
patients who experience progression in the brain during cri-
zotinib treatment may benefit from subsequent treatment with
an alternative ALK-targeted therapeutic.
ALK-dependent crizotinib resistance through amplification
of the ALK gene has been described, as have numerous ALK
kinase domain mutations that prevent crizotinib-mediated in-
hibition of the ALK fusion protein.7,26,27 Resistance to ALK
inhibition can also result from ALK-independent mechanisms,
including upregulation of alternative oncogenes/signaling
pathways.7,26,28 Specific crizotinib resistance mutations have
not been defined for all patients in this study; nonetheless, it is
likely that the antitumor activity observed with ceritinib en-
compassed patients who had a range of different crizotinib re-
sistance mutations, including patients who had no known/
defined resistance mechanism. The molecular profile after dis-
ease failure during prior crizotinib treatment was defined in
a small patient cohort in ASCEND-1, which demonstrated tumor
regression with ceritinib, irrespective of the cause of acquired
resistance.4 Similarly, a retrospective analysis of ceritinib in pa-
tients previously treated with crizotinib uncovered ALK resistance
mutations in seven of 23 patients; no statistical relationship was
observed between known ALK resistance mutations and response
to ceritinib.6,29
In addition to antitumor activity, there was a trend toward
a reduction in many patient-reported lung cancer–related
Table 3. Investigator-Assessed Intracranial Responses in Patients With Target
Brain Lesions at Study Entry
Best overall response
No. (%) of Patients With Target Brain








Abbreviations: CR, complete response; IDCR, intracranial disease control rate;
OIRR, overall intracranial response rate; PD, progressive disease; PR, partial
response; SD, stable disease; UNK, unknown.
*95% CI: OIRR, 23.1 to 68.5; IDCR, 56.3 to 94.3.
Table 4. Summary of Adverse Events (regardless of study drug relationship)
Occurring in $ 20% of Patients at All Grades or $ 2% of Patients at
Grades 3 or 4
Adverse Event
No. (%) of Patients by Grade
All Grades Grades 3 or 4
Total 140 (100.0) 100 (71.4)
Nausea 114 (81.4) 9 (6.4)
Diarrhea 112 (80.0) 9 (6.4)
Vomiting 88 (62.9) 6 (4.3)
ALT increased 61 (43.6) 24 (17.1)
Decreased appetite 57 (40.7) 5 (3.6)
Fatigue 51 (36.4) 9 (6.4)
Weight decreased 48 (34.3) 6 (4.3)
AST increased 45 (32.1) 7 (5.0)
Abdominal pain 44 (31.4) 2 (1.4)
Constipation 40 (28.6) 3 (2.1)
Cough 30 (21.4) 0
Pyrexia 29 (20.7) 4 (2.9)
Dyspnea 29 (20.7) 8 (5.7)
g-GT increased 25 (17.9) 17 (12.1)
Asthenia 25 (17.9) 6 (4.3)
Anemia 22 (15.7) 3 (2.1)
Blood ALP increased 21 (15.0) 4 (2.9)
Pneumonia 10 (7.1) 5 (3.6)
Hypokalemia 8 (5.7) 4 (2.9)
Hyperglycemia 7 (5.0) 4 (2.9)
Hypophosphatemia 7 (5.0) 3 (2.1)
Pericardial effusion 5 (3.6) 5 (3.6)
Dehydration 5 (3.6) 3 (2.1)
General physical health deterioration 4 (2.9) 4 (2.9)
Hepatic function abnormal 4 (2.9) 3 (2.1)
Abbreviations: ALP, alkaline phosphatase; g-GT, g-glutamyltransferase.
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Fig 2. (A) Improvement from baseline in
symptoms according to Lung Cancer Symp-
tom Scale score. (B) Worsening GI-related
symptoms from baseline according to the Eu-
ropeanOrganisation for Research and Treatment
of Cancer core-30 quality-of-life questionnaire
(QLQ-C30) symptom score. (C) Maintenance of
global health-related quality of life (QOL)
according to the QLQ-C30 score. SD, standard
deviation.
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symptoms. Patients appeared to experience an early im-
provement in lung-related symptoms, which was maintained
throughout treatment, but symptoms consistently worsened
at the end of treatment visits, potentially because of disease
progression. However, because these data are from a single-arm
study with no comparator, PRO data should be considered
with caution.
Considered together with results from ASCEND-1, these data
are encouraging for heavily pretreated patients with advanced
disease and high tumor burden, including those with disease
progression in the brain. High and durable responses are observed
when ceritinib is administered to patients who have already ex-
perienced disease progression during both chemotherapy and
crizotinib. Safety analyses are consistent with those reported
previously, and PROs were suggestive of improvement in lung
cancer–related symptoms. These results support the positive
benefit-risk profile of ceritinib compared with currently available
therapies in patients with ALK-rearranged NSCLC who have ex-
perienced progression during crizotinib treatment.
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Appendix
Supplemental Methods
Key exclusion criteria included hypersensitivity to any of the excipients of ceritinib; history of carcinomatous meningitis; the
presence/history of a malignant disease other than non–small-cell lung cancer that has been diagnosed and/or required therapy
within the past 3 years (exceptions to this exclusion included completely resected basal cell and squamous cell skin cancers and
completely resected carcinoma of any type in situ); and clinically significant, uncontrolled heart disease. In addition, patients who
had thoracic radiotherapy to lung fields 4 or fewer weeks prior to starting study treatment or who had not recovered from
radiotherapy-related toxicities were excluded, as were patients who hadmajor surgery within 4 weeks (2 weeks for resection of brain
metastases) prior to the start of the study drug or who had not recovered from adverse events of such a procedure and patients with
a history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.
Study Assessments
The European Organisation for Research and Treatment of Cancer core-30 quality-of-life questionnaire (QLQ-C30) comprises
30 questions that incorporate multi-item scales (functional, symptom, and global health and quality of life), and the comple-
mentary quality-of-life lung cancer–specific questionnaire (QLQ-LC13) consists of a single multi-item scale to assess symptoms and
adverse events. These surveys were used together with the visual analog Lung Cancer Symptom Scale (LCSS), whichmeasures major
symptoms for lung cancer, total symptom distress, normal activity status, and overall quality of life.
The questionnaires were self administered and were provided to patients at the first visit, on day 1 of cycles 2 and 3, and on day 1 of
every second cycle thereafter. All responses were collected at the beginning of each visit, prior to any interactionwith the study investigator.
Statistical Analyses
Efficacy analysis. On the basis of an exact binomial distribution, approximately 137 patients were required to test a null
hypothesis of an overall response rate (ORR) of 25% or less versus a target ORR of 38% or greater with a one-sided a of .025 and
90% power. If 137 patients were enrolled, and if at least 45 responses were observed (estimated ORR,$ 32.8%), the null hypothesis
would be rejected. The ORR (proportion of patients with a best overall response [BOR] of complete response [CR] or partial
response [PR]) was calculated, along with exact binomial 95% CI; patients with a BOR of unknownwere counted as nonresponders
for ORR calculations. The disease control rate rate, with the corresponding exact binomial 95% CI, was estimated as the proportion
of patients with a BOR of CR, PR, or stable disease (SD). The duration of response was defined as time from first documented
response to first documented disease progression or death. The time to response was defined as time from first dose of ceritinib to
first documented response. Progression-free survival (PFS) was defined as the time from the first dose of ceritinib to the first
documented progressive disease (PD) or death. A patient who had not experienced progression or died at the date of the analysis
cutoff or when he/she received any additional anticancer therapy in the absence of disease progression was censored at the time of
the last adequate tumor evaluation before the earlier of the cutoff date or the date of anticancer therapy. By default, if disease
progression or death was documented after one single missing tumor evaluation, the actual event date of disease progression/death
was used for the PFS event date. If disease progression or death was documented after two or more missing tumor evaluations, the
PFS time of these patients was censored at the date of the last adequate tumor evaluation without PD. Overall survival (OS) was
defined as the time from the first dose of ceritinib to death. The OS time for patients who were alive at the end of the study or who
were lost to follow-up was censored at the date of last contact. The median duration of response, time to response, PFS, and OS
times, and the associated 95% CIs, were estimated with Kaplan-Meier methodology.
Intracranial responses were assessed as CR, PR, or SD (defined as non-CR/non-PD for patients with nonmeasurable brain
lesions at baseline). The overall intracranial response rate was calculated as the proportion of patients with a BOR of CR or PR, and
the intracranial disease control rate as the proportion of patients with a BOR of CR, PR, or SD.
Patient-reported outcomes analysis. For each of the surveys, summary scores were generated from the responses for each
domain, per the respective scoring manuals. The change from baseline was assessed for each visit; patients with an evaluable
baseline score and at least one evaluable postbaseline score were included in the change-from-baseline assessments.
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Table A1. Protocol Deviations Leading to Exclusion From PPS
Protocol Deviation No. (%) of Patients in FAS (N = 140)
No postbaseline tumor assessment 9 (6.4)
No local documentation of ALK-positive status using the FDA-approved FISH test 3 (2.1)
Additional protocol deviations leading to exclusion by BIRC
No valid baseline tumor assessment* 2 (1.4)
No baseline target lesions† 26 (18.6)
Abbreviations: BIRC, blinded independent review committee; FAS, full analysis set; FDA, US Food and Drug Administration; FISH, fluorescent in situ hybridization; PPS,
per-protocol set.
*One patient was also included in the number of patients excluded because the patient had no local documentation of ALK-positive status with the FDA-approved FISH
test.
†One patient was also included in the number of patients excluded because the patient had no postbaseline tumor assessment.
Table A2. Patient Disposition
Variable
No. (%) of Patients
FAS (N = 140) Brain Metastases at Study Entry (n = 100)
Median (range) duration of follow-up, months 11.3 (0.1-18.9) 11.2 (0.2-18.9)
Treatment ongoing 51 (36.4) 34 (34.0)
Treatment discontinued 89 (63.6) 66 (66.0)
Reason for discontinuation
Adverse event 10 (7.1) 7 (7.0)
Death 5 (3.6) 3 (3.0)
Disease progression 56 (40.0) 43 (43.0)
Physician/patient decision 17 (12.1) 12 (12.0)
Lost to follow-up 1 (0.7) 1 (1.0)
Abbreviation: FAS, full analysis set.
Table A3. Whole-Body Responses Based on Investigator Assessments for PPS of Patients








Abbreviations: CR, complete response; DCR, disease control rate (CR + PR + SD); ORR, overall response rate (CR + PR); PD, progressive disease; PPS, per-protocol set;
PR, partial response; SD, stable disease; UNK, unknown.
*95% CI: ORR, 33.5 to 51.2; DCR, 76.0 to 89.5.
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Table A4. Whole-Body Responses Based on BIRC Assessments
Best overall response
No. (%) of Patients by Assessment Type
FAS (N = 140) PPS (n = 102) Brain Metastases at Study Entry (n = 100)
CR 0 0 0
PR 50 (35.7) 50 (49.0) 32 (32.0)
SD 38 (27.1) 37 (36.3) 32 (32.0)
Non-CR/non-PD 22 (15.7) 0 15 (15.0)
PD 15 (10.7) 12 (11.8) 11 (11.0)
UNK 15 (10.7) 3 (2.9) 10 (10.0)
ORR 50 (35.7) 50 (49.0) 32 (32.0)
95% CI 27.8 to 44.2 39.0 to 59.1 23.0 to 42.1
DCR 88 (62.9) 87 (85.3) 64 (64.0)
95% CI 54.3 to 70.9 76.9 to 91.5 53.8 to 73.4
Abbreviations: BIRC, blinded independent review committee; CR, complete response; DCR, disease control rate (CR + PR + SD); FAS, full analysis set; ORR, overall
response rate (CR + PR); PD, progressive disease; PPS, per-protocol set; PR, partial response; SD, stable disease; UNK, unknown.
Table A5. BIRC-Assessed Intracranial Responses in Patients With Target Brain Lesions at Study Entry
Best Overall Response
No. (%) of Patients With Target Brain Lesions at








Abbreviations: BIRC, blinded independent review committee; CR, complete response; IDCR, intracranial disease control rate; OIRR, overall intracranial response rate;
PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.
*95% CI: OIRR, 22.9 to 57.9; IDCR, 68.1 to 94.9.
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Baseline Cycle 3 Cycle 7
Baseline Cycle 5 Cycle 15A
B
Fig A1. (A) Computed tomography scan image showing a partial response in the brain in a patient with brainmetastases at baseline and at cycles 5 and 15 of ceritinib. The
patient had received no prior radiotherapy to brain. After 422 days of ceritinib treatment, the patient discontinued treatment because of clinical progression. (B) Magnetic
resonance imaging scan images showing a complete response in the brain in a patient with brain metastases at baseline and at cycles 3 and 7 of ceritinib. The patient had
received no prior radiotherapy to the brain. After 358 days of ceritinib treatment, the patient remained on treatment.
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